Capital Return / Corporate Action

Aurobindo Pharma Announces ₹800 Crore Buyback at ₹1,475 per Share

NSE

auropharma

BSE

524804

Aurobindo Pharma has approved a share buyback worth ₹800 crore at ₹1,475 per share, representing up to 0.93% of its equity capital, signaling confidence in its financial position.

PRICE-SENSITIVE TRIGGER

Event: Share Buyback Announcement

Type: Capital Return / Corporate Action

Impact: Positive

Immediate Effect: Supports stock price and enhances shareholder value.

Key Metrics

Buyback Size: ₹800 Crore
Buyback Price: ₹1,475 per share
Shares to be Bought Back: 54,23,728 shares
% of Equity: 0.93%
Mode: Tender Offer
Consideration: Cash

Timeline

Record Date: April 17, 2026
Completion: As per regulatory process

Highlights

Buyback Price: ₹1,475 per share

What Happened ?

Aurobindo Pharma Limited announced that its Board has approved a share buyback of up to ₹800 crore through the tender offer route.

The buyback will be executed at a price of ₹1,475 per share, offering shareholders an opportunity to exit at a premium.

Key highlights

Capital Return

₹800 crore cash outflow
Improves shareholder returns
Reduces excess cash reserves

Shareholder Value

Buyback price often at premium
Potential EPS improvement
Supports stock valuation

Ownership Impact

Buyback size:
- 0.93% of equity
Promoters eligible to participate

Strategic Intent

Reflects:
- Strong balance sheet
- Management confidence

Note: Small % buyback → sentiment positive but limited EPS impact.

Risk Analysis

Key Risks

Limited size (only 0.93%)
Opportunity cost of capital
Market expectations vs actual benefit

Worst Case Scenario

If premium is low, buyback may not significantly impact stock price.

Risk Level: Low

Company Commentary

Focus on capital efficiency
Returning surplus cash to shareholders
Strengthening investor confidence

Official Exchange Filing: Aurobindo Pharma Limited